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ABSTRACT

EXCESS SAMPLE SIZE AND THE ‘DELTA WOBBLE’ IN RANDOMIZED
CONTROLLED TRIALS
Michael A. Fischer and Alvan R. Feinstein. Department of Internal Medicine, Yale
University, School of Medicine, New Haven, CT.
To determine the occurrence and consequences of excess sample sizes in large
randomized controlled trials, we reviewed 158 randomized controlled trials, each
containing more than 100 patients, published in Lancet, Journal of the American Medical
Association, and New England Journal of Medicine during the three years 1990-1992.
Of 98 trials with statistically significant differences between control and experimental
groups, the reported P values were less than 0.001 in 27 (28%) and less than 0.01 in an
additional 35 (36%). Since sample sizes are usually calculated to provide P values of
0 05, the occurrence of values less than 0 01, and particularly below 0.001, suggests either
that sample size was excessive or that the investigators found differences much larger than
5 (the anticipated difference for “clinical importance”). The original anticipations were
difficult to determine, however, because sample size calculations were not reported
consistently: among the 158 trials, the details were presented completely in 78 (49%), but
wholly omitted in 58 (37%). Of 54 trials that stated the value of 5 and that found
“statistical significance,” 31 had P values below 0.01, but only 10 of these trials had
observed differences that were at least 25% larger than 5; in the remaining 21, the small P
value was attained only by excess sample size. On the other hand, 15 trials found P<0.05
and claimed statistical significance although the observed difference was at least 25%
smaller than 8.
The problems of excessive sample size (and resources) probably arise from the
customary Neyman-Pearson strategy, which tries to satisfy two (contradictory) statistical
hypotheses, thereby making sample size much larger than what is needed for a single null
hypothesis. The excessive sample size may then allow “statistical significance” to be
found and emphasized for differences much smaller than what was originally anticipated.
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I.

INTRODUCTION

“The value for which P-.05, or 1 in 20, ... is convenient ...
as a limit in judging whether a deviation is to be considered
significant or not.” 1,p 44

Sir Ronald Fisher originally made the above definition in 1925. Today the
threshold of P below 0.05 remains the principal criterion for statistical significance, often
representing the difference between research that changes current practice and research
that does not. In many clinical trials, however, the authors report P values that are much
smaller than 0.05. Very small P values can arise either because the difference in the event
rates reported is much larger than originally anticipated or because the sample size was
excessively large.

This research was aimed at documenting the frequency with which randomized
controlled trials in major medical journals report very small P values, and to suggest
possible reasons for the phenomenon. The research data were obtained by reviewing the
sample size calculations and the subsequent results described in the published trials.

The remainder of this section contains a review of previous literature on sample
size calculation in randomized controlled trials. Section II describes the methods used to
assemble a group of randomized controlled trials for review and to abstract data from
those articles. Section III presents the main results of the study, including the range of P
values in the reviewed articles, the extent of reporting for sample size calculations, and the
differences between the reported and the originally anticipated event rates. Section IV
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discusses the implications of the results in Section III and shows some illustrative
examples of calculations of sample size. Section V contains the conclusions.

A.

Literature Review of Studies Reporting on Sample Size Calculation

Previous studies of the reporting of sample size calculation in randomized
controlled trials have repeatedly shown that most authors do not report the details of their
sample size calculations. In 1978 Ambroz et al. reviewed 172 randomized controlled trials
and found that none of the publications reported a sample size calculation 2. A 1982
review of 67 randomized controlled trials found that 12% of the articles reported the
details of the sample size calculation and 3% provided partial information about the
sample size calculation \ In 1986, a survey of the breast cancer literature by Liberati et al
revealed that 20 (32%) of 63 articles had reported sample size calculations in the text4. In
follow-up phone calls, 13 more sets of authors provided the details of sample size
calculation that had not been presented in the text4. In a 1987 review, 5 (11%) of 45
articles reported sample size calculations 5. In 1990 AJtman and Dore found some
improvement in completeness of reporting: 31(39%) of 80 trials reported details of the
sample size calculations and only 27(34%) of 80 articles made no mention of advance
consideration of sample size 6.

Two large literature reviews in 1994 showed that reporting of sample size
calculation methodology had become more widespread than in 1978 but was still far from
universal. In a review of the obstetrics and gynecology literature from 1990 and 1991,
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Schulz and co-authors found that only 50 (24%) of 206 articles reported sample size
calculations 7. These authors also found considerable variation between journals in the
extent of reporting of sample size calculation 7. Moher et al., in a sample of articles from
1975 to 1990, found that 33(32%) of 103 reported sample size calculation 8. The
proportion of articles reporting sample size calculation had increased over time, from 0%
in 1975 to 43% in 1990 8.

B.

Studies Arguing for Larger Sample Sizes

The attempt to determine the proper sample size for a randomized controlled trial
can be seen as both a practical and an ethical concern:
A study with an overlarge sample may be deemed unethical through the
unnecessary involvement of extra subjects and the correspondingly
increased costs ... On the other hand, a study with a sample that is too
small will be unable to detect clinically important effects. Such a study may
be scientifically useless, and hence unethical in its use of subjects and other
resources. 9,p 1336

Over the last two decades, the predominant argument made in the medical literature has
been for larger sample sizes.

The importance of large samples to avoid type II error, or false negative
conclusions, in randomized trials was brought to prominence by Freiman et al. 10 in an
influential article, nearly 20 years ago, that noted many trials reporting no difference
between control and experimental groups were in fact not able to rule out differences as
large as 25 or even 50 percent. Freiman et al. urged that much larger sample sizes would
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be needed to state conclusively that there was no difference between control and
experimental groups. In a recent article that revisited the issue originally raised by
Freiman et al., Moher et al. found that many clinical trials reporting no difference still did
not have samples large enough to exclude effects of 25 or 50 percent8.

On the other hand, during informal reviews of the literature, several readers had
noted extremely small P values, suggesting that sample sizes were substantially larger than
needed to achieve the boundary of 0.05. The current study was evoked by questions
about the frequency and sources of the “too-large-sample” phenomenon.

D.

A.

METHODS:

Assembling the Articles

For this review, I chose randomized controlled trials published in Lancet, New
England Journal of Medicine, and Journal of the American Medical Association during
the three year period from 1990 through 1992, inclusive. This choice follows the method
of two prior studies. In one of the most widely cited reviews of statistical methods in the
medical literature, Freiman et al. 10 examined articles from several journals, but more than
one-half of the articles came from these three journals. In their later review of the same
topics, Moher et al. 8 also examined articles in those same three journals. With the

5

emphasis on large clinical trials, I restricted my search to articles with a sample size of at
least 100 patients.

Table 1 summarizes the literature search and the criteria for exclusion of articles.
Using the Medline computer program in the summer of 1994,1 restricted the search to
“Clinical Trial," "Multicenter Study," and "Randomized Controlled Trial." The search
produced 1003 articles, which were reviewed to determine appropriateness for this study.
I made certain simple exclusions by inspecting the abstracts cited by Medline, but other
exclusions required review of the text of the articles. The search produced many articles,
including letters (276), editorials (56), reviews (8), meta-analyses (9), and news
summaries (16), all of which I excluded. The 238 articles that described trials containing
fewer than 100 patients were also excluded, as well as 102 articles that were not
randomized controlled trials, having been obtained via the headings “Clinical Trial," and
"Multicenter Study". Additional exclusions were 84 trials whose primary outcome
measure was not a rate or proportion, 21 trials that were designed to show equivalence
(rather than efficacy) between control and experimental groups, 11 trials that were
designed to demonstrate vaccine efficacy, eight trials that had multi-stage randomization
schemes or other complexities that made them inappropriate for this analysis, and six that
were follow-up cohort studies of patients from prior randomized controlled trials.
Appendix A lists full citation information on the included articles.

Table 1: Details of literature search

NEJM

Lancet

JAMA

Total

Articles Identified

396

490

117

1003

Excluded because:
Letter to editor
N<100

82
84

190

4

131

23

276
238

Not rand, controlled trial

36

50

16

102

Not measuring event rate

30

26

84

Editorial

38
47

8

1

56

Trial for equivalence

14

6

1

21

“News”

1
4

2
7

13

16

0

2
1
3

1
6
3

11
9

0

TOTAL EXCLUDED
TOTAL KEPT

Vaccine trials
Meta-analysis
Review article
Complex randomization
Follow-up studies

6

8
8

2

1
2
4

6

312

436

97

845

84

54

20

158
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After the exclusions cited in Table 1, the remaining 158 articles were each
reviewed and suitably excerpted for descriptions of the sample size calculations. For trials
that reported a statistically significant difference between experimental and control groups,
the magnitudes of the main difference between groups, and the corresponding P value,
were recorded. The remainder of this section describes the recorded components of the
sample size calculation.

B.

Introduction to Neyman-Pearson Equation

The most widely accepted method for calculating sample size is the NeymanPearson equation, shown below:

(Za + Z/j)2 x[2x;rc x(1-ttc)]

n ~-s2-

( 1 )

In this equation, n represents the number of subjects that will be required in each of two
groups. Za represents the Z-score that corresponds to the designated value of a, which is
the risk of type I error that the authors are willing to accept. Zp represents the Z-score
that corresponds to the designated value of P, which is the risk of a type II error. tcc
represents the estimated value for the event rate expected in the control group, and the
quantity [2 * nc x (1-tcc)] represents the variance of that rate. 5 represents the anticipated
difference that the authors hope to find between rates in the control and experimental
groups.
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The Neyman-Pearson sample size calculation requires two basic decisions: the first
is defining the levels of significance that will be used as cutoff points for a and P, and the
second is estimating event rates. If both of these decisions are fully described, a reader
can replicate the sample size calculation and, aware of statistical assumptions made in trial
design, can understand the importance of the subsequently reported P value.

The level of significance for rejecting the null hypothesis is defined by the
designation of a, typically 0 05 and traditionally two-tailed. It corresponds to a Gaussian
Za value of 1.96. The a value of 0.05 implies a 5% risk of a type I error, in rejecting a
true null hypothesis, so that the observed finding arises from chance alone. The risk of
type II error, in rejecting a true alternate hypothesis of a large difference between groups,
is defined by P, which can have various values, but is often designated at 0.10. P can be
either one- or two-tailed

The assigned value of P is often stated implicitly as the power

of the study, which is calculated as 1-P, so that the most commonly assigned power for a
study is 90%.

For the studies that provided a sample size calculation, I recorded whether the a
or P designations were described, and also listed as one- or two-tailed. Presentation of the
power of a study was considered equivalent to presenting the value of p.

The other important decision in sample size calculation is a prior estimation of
event rate in the control group(7tc) and the change(5), i.e. delta, that the authors believe
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would represent a clinically significant finding In Equation 1 the required components are
the variance [27ic( 1-7tc)] of the rate in the control group in the numerator and 5 in the
denominator. Many authors do not present both of these designations. When authors
present only the 5 that they hoped to find, it is helpful for reviewing the final outcome of
the trial, but does not provide enough information for the reader to re-create the sample
size calculation. Many authors do not cite the absolute difference which they hoped to
find for 5, but instead describe 0, the desired proportional (or relative) change, which
would usually be calculated as 5/7tc. The presentation of only 0 gives some information
about the authors’ assumptions, but does not allow re-creation of the sample size
calculation. The sample size calculation can be replicated only if authors provide their
prior designation of 7tc together with any citation of 7te (the anticipated rate in the
experimental group), 5, or 0.

For the articles that provided sample size calculations, I recorded which of these
features were reported

10

III.

A.

RESULTS

Range of P Values

Of the 158 articles in this sample, 104 reported statistically significant differences
between the control and experimental groups. Of those 104 articles, the six that did not
use P values in discussing the results were not included in this section. Table 2 shows that
among the 98 articles with statistically significant outcomes, 27 (28%) reported P values
less than or equal to 0.001, 35 articles (36%) had P values that were between 0 01 and
0.001, and the remaining 36 articles reported P values between 0.05 and 0.01.

Given that P<0.05 is the commonly accepted threshold for statistical significance,
it seems surprising that over 25% of the articles reported P values 50 times smaller than
the threshold value (i.e. <0.001). Two possible explanations could account for these
extremely small P values: the observed difference (hereafter referred to as do) found to be
statistically significant might have been much larger than the difference (6) that the authors
expected to find; alternatively, the number of patients in the trials might have been much
larger than needed to achieve significance at the P<0.05 level* . To assess the frequency
of these explanations, the original sample size calculations must be examined to determine
the event rates that were estimated when the trial was designed.

Section III.C will point out a third explanation - altered variance - for small P values, and the example
in Section IV.B.3 will expand on that explanation

Table 2: Range of P values in trials with statistically significant outcomes

P value

Number of articles(%)

P<0.001

27 (28%)

0.001<P<0.01

35 (36%)

0.01<P<0.05

36 (37%)
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B.

Sample Size Calculations

1.

Presentation of Sample Size Calculations

Table 3 summarizes the ways in which authors reported their sample size
calculations. Of the 158 large, randomized controlled trials under analysis, 58 (37%) were
reported with no description of how sample size was calculated and with no reference to a
previously published calculation. Of 100 (63%) that provided at least some description of
the calculation, 12 required reference to a prior publication to find some or all of the main
components in the sample size calculation The cited 100 articles were stratified into the
several groups shown in Table 3. The first column shows that 78 reports provided prior
designations of event rates. The remaining 22 articles provided less detailed descriptions
that would limit a reader’s ability to fully understand the assumptions that went into the
sample size calculation.

The rows of Table 3 show the extent to which authors noted their prior
designations of a and p. For the sake of simplicity this table does not include whether
authors indicated if their designations of a and p were one- or two-tailed

Almost half of

the authors who presented a value of a classified it as one- or two-tailed (42/87), while
very few authors noted whether their values of P were one- or two-tailed (6/91). The first
row shows that 83 articles (53% of the total sample) presented both a and P designations.
Only four authors (3%) presented only a values (2nd row) and eight (5%) reported only P
values (3rd row). The fourth row of Table 3 shows that in addition to the 58 articles that
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Table 3: Elements reported for sample size calculation

Designations of
a and (3
described

Designation
of
7tc and 5

Designation
of
5 described,

described *

but 7tc not
described

Designation
of
9 described,
but neither

No event
rate
designations
described

TOTAL

7tc nor 5
described

67

5

9

2

83

a alone
described
Designation of

2

1

0

1

4

(3 alone
described

4

1

3

0

8

5

0

0

58

63

78

7

12

61

158

Designation of

Neither a nor
(3 designation
described
TOTAL

;

7ie or 9 were acceptable substitutes for 5
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did not describe any sample size calculation, five others (with some description) did not
include their designations of either a or (3.

The columns of Table 3 show the frequency with which authors reported their
prior estimations of outcome rates in the control and experimental groups. As noted
earlier, proper interpretation of results requires knowledge of nc and of 5, although the
value of 6 could be calculated by subtraction if nc and ne are described, or by appropriate
multiplication if 7tc (or

7te)

and 9 are described. The first column shows that 78 articles

(49% of the total sample) either provided both

7ic

and 5, or provided

kc

and enough

information for 5 to be easily calculated. Smaller numbers of articles presented either 5
alone (2nd column, 7/158, 4%) or 9 alone (3rd column, 12/158, 8%). No articles in the
sample reported nc alone without some indication of the desired change, but the fourth
column shows that, beyond the 58 articles with no information on the sample size
calculation, only three articles gave no indication of the estimated event rates or desired
differences.

2.

Completeness of Reporting for Sample Size Calculation

As noted earlier, a complete description of the sample size calculation would allow
understanding of the methods used by the investigators. The 67 trials in the upper lefthand comer of Table 3 provided complete or near-complete descriptions of sample size
calculations, limited only by inconsistent reporting of whether a and (3 were one- or two-
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tailed (four articles reported this information for both a and P). Similarly, for the 11
articles in the rest of the first column of Table 3, values of nc and 5 are described
(although a and P are not both reported) so that a reader could appreciate the connotation
of the P values reported by the authors.

For the 19 articles in the middle two columns of Table 3, the reader would be
hard-pressed to understand the sample size calculation. A determined reader could make
multiple guesses at the designation of 7tc, perhaps getting a sense of the prior estimates but
the process would be quite laborious. For the 61 articles in the right-hand column of
Table 3, there is no way for a reader to understand the sample size calculation, especially
for the 58 articles that provided no details at all.

In summary, only 4 of the 158 articles (3%) reported all of the information needed
to understand the sample size calculation, but an additional 63 articles (40%) offered
almost complete information. Eleven articles (7%) provided incomplete information but
described the critical rates that would allow the reader to evaluate the outcome of the trial.
Nineteen additional articles (12%) offered information that might allow for a general sense
of the sample size calculation, but was too limited for full evaluation of the results. Sixtyone articles (39%) did not provide information that would allow any realistic attempt at
understanding the sample size calculation. There was no correlation between the actual
sample sizes in the trials and the extent of reporting of the sample size calculations.
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Overall, 78 of the articles (49%) provided enough information for readers to understand
the important components of the sample size calculation.

For the 78 articles which presented their prior designations of event rates, if
significant differences were found, readers could evaluate the magnitude of the P values
reported

Table 4 shows that of the 158 total articles reviewed, 54 both described 7ic and

5 and reported statistically significant outcomes. The following sections will compare
prior estimates and reported results for these 54 articles.

C

Example of P Value Calculation

The P value used to determine statistical significance is based on a Z-score derived
from the following equation:

Z=

(2)

In this equation, the numerator, do, is equal to pc (the outcome rate in the control group)
minus pe (the outcome rate in the experimental group). The denominator for this
calculation is the standard error of the difference between groups (SED). For its
calculation, p is the average outcome rate (i.e. the average of pc and pe), ric is the number
of patients in the control group, and n^ is the number of patients in the experimental
group.
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Table 4: Criteria for inclusion of articles in analysis of 8 versus d0
Articles reporting a statistically significant
d0 with a P value

Articles that
reported both
7TC and 6
Articles that did not
report both
7tc and 5
TOTAL

|

Yes

No

TOTAL

54

24

78

44

36

80

98

60

158

18

Higher Z-scores correspond to lower P values, for example a Z-score of 1.645
corresponds to a two-tailed P value of 0.10 while a Z-score of 1.96 yields the familiar
two-tailed P value of 0.05. Equation 2 shows that a Z-score could increase in three ways.
An increase in d0 would enlarge the numerator; alternatively, either an increase in n<; or rie
or a decrease in the variance would reduce the denominator. The next section will
compare the range of observed do values and the anticipated 8 values in this group of
articles.

D.

Differences Between d0 and 8

Table 5 shows that, of the 54 articles which reported both prior designations of event rates
and statistically significant outcomes, the observed value of d0 was greater than or equal to
the prior assignment of 5 in 29 cases, but 25 articles reported statistical significance for a
d0 that was smaller than the prior designation of 8. We have named this latter
phenomenon “8 (delta) wobble” and will explain the term more completely later in the
Discussion. In four extreme instances, the observed do was at least 50% smaller than the
anticipated 8

As an example of “8 wobble,” in one of the articles" included in the

second-to-last row of Table 5, a 8 value of 0.30 was designated for the purposes of
sample size calculation, but a statistically significant d0 of 0.152 was presented in the
results section. Thus for this article do was smaller than 8 by 49% [i.e. (d0 - 8)/8 = (0.1520.30)/0.30 = - 0.49], At the other extreme, in one of the articles12 included in the first row
of Table 5, a 8 of 0.20 was

Table 5: Frequency of values for the proportionate difference (d0-5)/5
(Negative percentage for do<5, positive percentage for do>5)

Percent difference between
do

and

Number of articles

5

>50%

10

25% to 50%

6

0% to 25%
0%

12

-25% to 0%

1
10

-50% to -25%
<-50%

11
4

20

designated for sample size calculation, but a

do

of 0.37 was presented in the results

section. For this article d0 was greater than 5 by 85% [(0.37-0.20)/0.20 = 0.85],

The final row of Table 5 show that of the 25 articles with “5 wobble,” i .e. a do
value less than the prior designation of 5, four presented a statistically significant

do

was less than half as large as 5 (first row). An additional 11 articles presented

values

d0

that

that were smaller than 5 by a proportionate increment between one-quarter and one-half
(second-to-last row). Seven of the 25 articles with “5 wobble” presented a statistically
significant

do

Table

value that was less that 5 by an absolute increment of more than 0.10.

6

shows the relationship of discrepancies between

of P values reported. As noted previously, increased

do

do

and 5 to the magnitude

values could cause very small P

values. The first two rows of Table 6 show that of the 31 trials which reported 5 and had
P values less than or equal to 0.01, 10 had

do

values more than 25% larger than the prior

designation of 5, but 12 of the 31 trials with P<0.01 had

d0

values that were smaller than

the prior designation of 5. Table 6 demonstrates that the very small P values are not
restricted to trials reporting

do

much larger than 8. Indeed, the final three rows show that

even some of the trials that commit “8 wobble” report very small P values.
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Table 6: Frequency of values for the proportionate difference (do-5)/5, categorized
by magnitude of reported P-value in statistically significant trials. Last row
contains those articles which did not report original designation of 5.

Percent difference
between d0 and 5

P<0.001

0.001<P<0.01

0.01<P<0.05

Total

>50%

4

2

4

10

25% to 50%

3

1

2

6

0% to 25%
0%

2
1

6

4

12

0

0

-25% to 0%

0

6

4

1
10

-50% to -25%

1

4

6

11

<-50%

0

1

3

4

Total reporting 5

11

20

23

54

No 6 described

16

15

13

44

Grand Total

27

35

36

98
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IV.

A.

DISCUSSION

Reporting of Sample Size Calculations

The current finding, that 43% (67/158) of a group of published randomized
controlled trials presented full details of sample size calculations, was only slightly higher
than the 39% found in a 1990 review 6 and was identical to the rate noted in an analogous
review published in 1994. 8 The finding that 39% (58/158) of articles reported no details
of sample size calculation was also similar to the rate noted in a 1990 review 6.

Although the details of sample size calculation are now reported more often than
noted in the first such reviews almost 20 years ago 2, reporting is still far from complete
In a 1994 review, Moher et al. suggested:
that authors should report sample size calculations and that
the following information should be contained in all
published reports of RCTs: (1) The primary dependent
measure(s) should be clearly identified. (2) A clinically
important treatment effect should be specified. (3) The
treatment effect should be clearly indicated as being an
absolute or a relative difference (4) The statistical test,
directionality, a level, and statistical power used to estimate
sample size should be reported. 8 p 124
This suggestion was re-iterated in an article later in 1994 by The Standards of
Reporting Trials Group, an international committee established to address reporting of
randomized controlled trials

n.

In light of the consequences that are about to be

discussed, editors might follow the recommendations of Moher et al and become more
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demanding in asking authors to report their pre-trial assumptions when sample size was
calculated.

B.

Very Small P Values

As noted in Table 2, more than 25% of the trials with statistically significant results
reported P values that were <0.001. As shown in Equation 2, these excessively small P
values could have come from unexpectedly large values of do, but Table 6 shows that only
10 (32%) of the 31 articles with P<0.01 found d0 to be substantially larger than 5. The

remainder of this section will show, however, that even for those 10 articles, the large d0
values were not likely to have caused the excessively small P values.

1.

An Example of an Article with d0 Much Larger Than 8

In one article where 6 was designated as 0.20 but do was found to be 0.37, this
distinction was reported as having a P<0.001 12. The Z-score for this result can be
calculated using Equation 2. In the article cited, pc was 0.77, pe was 0.40, rtc was 104 and
ne was 95

n.

p can be approximated as the weighted average of 0.77 and 0.40, which

yields 0.593*. The Z-score is thus:

* This value is calculated as an average weighted by the number of subjects in each group:

_ ”cPc+nePe
P =+ n.

(104x0.77)+(95x0.40)
- 0.593
104 + 95

24

Z=

0.77-0.40

= = 5.31

1

1

(3)

°

i m
| On

+
1

i

_i

r i
1
10.593(1-0.593)

Since a Z-score of 3.80 corresponds to a P value of 1x1 O'4, this finding would not only
result in P<0.001, but would yield an infinitesimally small P value in the range of
1.0 xlO'7

2.

Rp31.

Effect of Discrepancy Between d0 and 8 on P Values

If the do in the above example had been the expected 0.20 instead of 0.37, i.e., if pc
was 0.60, the Z-score would be calculated as follows:

L/1

1
o
L/i
o

'-/I

O
o

l/N

0.60-0.40

2.82
i

r

(4)

104 + 95_
The corresponding P value would be less than 0.00515,p 281. Although much larger than
the previous result for P, this value is still 10 times smaller than the boundary of 0 05 for
achieving statistical significance.

3.

Effect of Discrepancy Between pc and nc on P Values

In the cited article, however, not only was d0 much larger than 5, but the observed
event rates themselves were considerably larger than the values assigned prior to the
study. The authors had previously estimated rates of 0.25 for the control group and 0.05
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for the experimental group 12. If these outcome rates had actually been found, the Z-score
calculation would have shown:
0.25-0.05

r i 11
r
10.155(1-0.155)
104 + 95_

3.89,

(5)

which corresponds to a P value of lxlO'4 14,p 31

In this example the discrepancy between the observed and estimated event rates
affected the variance term in the denominator. The closer p is to 0.50, the larger the
variance will be and the smaller the Z-score will be. The discrepancy between predicted
and reported rates in this example moved p very close to 0.50, but the P value was still
reported as statistically significant by a wide margin. The more striking point, however, is
that the Z-score calculated in Equation 5 represents the clinical outcome expected by the
authors, but the corresponding P value is extremely small. If the very small P value is due
neither to large do values nor to discrepancies between pc and 7tc, the only remaining cause
for the small P values is excessively large sample sizes.

C

The Phenomenon of “S Wobble ”

In addition to showing that increased d0 values seldom cause very small P values,
Table 5 and Table 6 reveal an additional phenomenon. As noted in Section III.D, 25 of
the 54 articles in Table 5 reported d0 values smaller than 5; indeed 15 of the “statistically
significant” d0 values were at least 25% smaller than 6. If the 5 value entered into the
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Neyman-Pearson equation represents the minimum boundary to be regarded as clinically
significant, the frequent citation of “significance” for d0 values much smaller than the pre¬
assigned 5 calls into question the initial design of the trial. The remainder of this section
will show a hypothetical sample size calculation to demonstrate that the Neyman-Pearson
equation converts 5 into a “wobbly” parameter. The calculated sample sizes will allow
values of d0 much smaller than 5 to be declared statistically significant.

The values in the example below are chosen arbitrarily, but the results will hold for
any set of values if readers want to replicate the exercise. The Neyman-Pearson
calculation shown in Equation 1 in Section II B is the standard method used for
calculating sample sizes. The elements of the calculation were described in Section II B
and will not be repeated here.

1.

Calculation of the Sample Size

For this example, I will assume that the mortality rate of 0.20 with current therapy
for disease X is to be tested against a new treatment that is expected to reduce the
mortality rate to 0.10. Following convention, the researchers designate an a value of 0.05
(two-tailed) and a (3 value of 0.10 (one-tailed) for the purposes of sample size calculation.
The sample size calculated using the Neyman-Pearson equation will be as follows:

(1.96 +1.282)2 x [2 x 0.2 x (1 - 0.2)]
n>-;-= 336
0102

(6)

27

The researchers therefore recruit a total of 672 patients to their study, 336 to receive
current therapy and 336 to receive experimental treatment. With this backdrop, I will now
consider possible outcomes.

2.

Scenario 1: d0 Equal to 8

In the first scenario, the researchers find exactly what they had expected.
Mortality in the control group is 67/336, or 0.199, while mortality in the experimental
group is 34/336, or 0.101. To test the statistical significance of these findings, the Z score
is calculated with Equation 2 to show:

0.199- 0.101

I0.15(1-0.15)

1
L336

+

1

1

3.56

(7)

336J

The corresponding two-tailed P value for this result is 0.0002I5,p 28°, which is much
smaller than the anticipated P=0.05, although the d0 found by the researchers almost
exactly equals the prior designation of 5.

3.

Scenario 2: d0 smaller than 8, but is Statistically Significant

In the second scenario, mortality in the control group is again 67/336, or 0.199,
but mortality in the experimental group is 47/336, or 0.140. This d0 of 0.059 is much
smaller than what was hoped, but calculation of a Z score reveals:
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0.199-0.140
Z=
1

r
0.170(1-0.170)

1

i

]

= 2.04

(8)

.336 + 336.

This corresponds to a P value of 0.041415,p 28°. Armed with this result, the investigators
can now present this d0 of 0.059 as statistically significant, although it is almost half of the
5 value of 0.10 which they designated as a difference worth finding before the trial began.

4.

Scenario 3: d0 Smaller than 8, but not Statistically Significant

In a third scenario, control group mortality remains at 67/336 (0.199), but one
additional experimental group patient dies, so that experimental group mortality is 48/336,
or 0.143. The do of 0.056 is again smaller than the prior designation of 8. Calculation of
the Z-score shows:

0.199-0.143
1

0.171(1-0.171)

1

1 1

1.93

(9)

.336 + 336.

This corresponds to a P value that is slightly greater than 0.0515,p 280, so that the
investigators cannot claim the result is significantly different from zero. Persevering, the
researchers recall that the Zp term in the sample size calculation was 1.282, corresponding
to a one-tailed (3 of 0.10. A Z-score for the alternate hypothesis can be calculated using
the following formula:

.

_S-d0

A

SED

(10)
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This is almost the same Z-score formula shown in Equation 2, but differing in the use of
the quantity 5- d0 in the numerator*, and it results in the following calculation:

ZA

0.10-0.056

1
Jo,171(l - 0.171)

1

1

(11)

336 + 336_

Since this value is greater than the threshold value of 1.282 used in the sample size
calculation, the investigators can reject the alternate hypothesis of a large difference
between groups.

The investigators can now claim they have proven that there is no

important difference between the two treatments, as their results excluded a difference of
0.10.

5.

A Zone of Double Significance

A particularly interesting result arises, however, if we return to the scenario in
Section IV.C.3, and to the Z-score calculated in Equation 8. If, for that same result, the
researchers had calculated a ZA for the alternative hypothesis:

0.10-0.059
ZA

1
J0.170(1-0.170)

1

(12)
1 1

336 + 336_

The SED for the alternate hypothesis is properly calculated as follows:

seda =
11

In this example, both the above calculation and the calculation shown in the denominator of Equation 11
produce a value of 0 029. The standard calculation of SED will be used for the remaining examples.
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This result is greater than the prior Zp value of 1.282, and the investigators can declare
that they have proven that there is no important difference between groups, as this result
excludes a difference of 0.10. For this result, therefore, the investigators have achieved
double statistical significance. The difference between groups is both statistically
significantly greater than zero (Equation 8) and is also statistically significantly smaller
than the difference initially defined as clinically significant (Equation 12).

6.

Neyman-Pearson Equation Shifts Threshold for Statistical Significance

Although the investigators stated initially that a difference of 0.10 between
treatments represented the boundary for clinical importance, the sample size calculated
with the Neyman-Pearson equation would in fact allow them to declare statistical
significance for a d0 as small as 0.059, or any larger value

At that same level of do, and at

any smaller value, the investigators could declare that their result was statistically
significantly smaller than 0 10. The crucial observation here is that when sample size is
calculated with the Neyman-Pearson equation for this example, the investigators will find
a statistically significant result no matter what value emerges for do. The particular values
shown in Section IV.C.5 will even achieve double significance; thus, the threshold for
significance is no longer the clinical threshold that was used in trial design. In addition,
when the final result does equal the threshold defined as clinically significant for trial
design, the P value is orders of magnitude smaller than the 0.05 value that conventionally
determines statistical significance.
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D.

Calculation of Implicit Thresholds

The example in the preceding section demonstrated some of the consequences of
using a sample size generated by the Neyman-Pearson calculation. In this section I will
show how those consequences arise. The crux of this argument is that the NeymanPearson calculation uses both Za and Zp, thereby incorporating both null and alternate
hypotheses in one formula. In the analysis of results, however, these hypotheses are
evaluated separately, each with an individual calculation.

If one calculated a sample size considering only the possibility of type I error, the
sample size calculation would be as follows:

n>

(Za)2 x[2x^x(l - n)]
S2

This differs from the Neyman-Pearson calculation in that Zp is not included

(13)

Conversely, if

one calculated a sample size with concern for type II error only, the following equation
would be used:

(Zp)2 x[2x^x(l -n)]

(14)

In this case, Za has been excluded from the numerator. Additionally, the denominator
term (5 - d0) reflects the increment at which a difference of 5 will be ruled out at the Zp
level of significance.
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Combining the previous two equations with the results of the example from the
previous section, I will now demonstrate that the thresholds for statistical significance are
not those demarcated in the Neyman-Pearson equation. In Equation 6, the calculated
sample size was 336 patients per group. With this sample size, consider Equation 13.
Inserting 336 for N, 1.96 for Za, and keeping the same term in the denominator, the result
is as follows:

(1.96)2 x [2x0.2 x (1-0.2)]
336 =

(15)

I

2

Rearranging equation 15 to solve for 5 produces:

5=

|(1.96)2 x [2x0.2 x (1-0.2)]
336

= 0.060

(16)

The implication of the above calculation is that although a 5 value of 0 .10 was designated
when the Neyman-Pearson equation was used to calculate sample size, the result in fact
represents an implicit 5 designation of 0.060. In other words, although the study design
designates a difference of 0.10 as clinically important, differences as small as 0.060 will be
found to be statistically significant. This result explains both the findings summarized in
section III.D and the outcome of the example trial presented in section IV.C.

The same process can be utilized for the calculation shown in Equation 14. Again
combining that equation with the result of Equation 6, but omitting the intermediate steps.
the final result will be as follows:
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S-dQ

/(1.282)2 x 2 x 0.2 x(l-0.2)l

=

J--------- = 0.040

0 v

336

( 17
v

Since the prior designation of 5 in this example was 0.10, this result shows that for any d0
value of 0.060 or smaller, the ZA value for the alternate hypothesis will be greater than
1.282 and the alternate hypothesis of a large difference between control and experimental
groups will be rejected.

The results of Equations 16 and 17 converge around a do value of 0.060. The
preceding paragraphs show that for the sample size determined with the Neyman-Pearson
calculation in Equation 6, any value larger than 0.060 will be statistically significantly
greater than 0, while any value smaller than 0.060 will be statistically significantly smaller
than 0.10. In fact, since the SED is used for Z-score calculation (see Equation 2) and the
variance of the control group rate is used in the standard form of the Neyman-Pearson
formula (see Equation 1), the actual numbers in Section IV.C stretch further, so that
values somewhat smaller than 0.060 will be statistically significantly greater than 0, and
some of these values will also be statistically significantly smaller than 0.10. In practical
terms, then, the Neyman-Pearson sample size calculation has guaranteed a statistically
significant result in one direction or the other, and has even created a zone of double
significance. The value 0.060 has now become the threshold at which the therapy being
studied will be declared effective or ineffective, although this value is barely half of the
value originally designated by the investigators. This result is not particular to the
numbers chosen for this example, and will be found with any other set of values that are
chosen for the illustration.
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V.

CONCLUSION

This paper has attempted to show consequences of excess sample size in large
randomized controlled trials. Since a landmark paper by Freiman et al. almost 20 years
ago, most discussion of sample sizes has focused on the need for larger samples The
results of the present study, however, suggest that enlargement of sample sizes, and in
particular the use of the Neyman-Pearson equation to calculate these large samples, may
have two important unintended consequences.

The first consequence is that with the large sample sizes generated by the NeymanPearson equation, many results will produce extremely small P values, despite the general
acceptance of 0.05 as the threshold for a statistically significant finding. As noted in the
introduction, an overly large sample generates excess cost and requires an excessive
number of patients. As research handing dwindles, the excessive costs of oversized trials
represent a substantial overuse of resources.

The second consequence of sample sizes calculated with the Neyman-Pearson
equation is that the quantitative threshold for an impressive difference is reduced to almost
half of the initial level. Thus, whatever 5 investigators designate at the outset of the trial,
the d0 that can be declared statistically significant will be considerably smaller than the
original value of 5, we have named this phenomenon “8 wobble.” The “wobbliness” of the
boundary for clinical significance defined for sample size calculation undermines the
clinical judgment used in originally defining 5.
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The problems of excessively small P values and “5 wobble” suggest that the
Neyman-Pearson strategy of sample size calculation requires serious reevaluation

It is

beyond the scope of this paper to suggest alternative methods for sample size calculation.
Until such methods are developed, however, editors can address the problem of “6
wobble” by requiring investigators to state both 5 and d0, and to justify reporting of
statistically significant d0 values which are smaller than the 5 initially designated as
clinically significant.
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